Investment Rating - The report maintains a BUY rating on BeOne Medicines with a target price of US$392.43, indicating a potential upside of 23.8% from the current price of US$316.99 [1][2]. Core Insights - BeOne Medicines achieved its first full-year profitability in FY25, driven by strong sales of its BTK inhibitor, Zanubrutinib (Zanu), which generated US$3.93 billion in sales, reflecting a 49% year-over-year increase [1][8]. - The company has provided FY26 revenue guidance of US$6.2–6.4 billion, which is slightly below previous estimates of US$6.6 billion, but the outlook remains positive due to Zanu's expanding market share and multiple upcoming clinical and regulatory catalysts [1][8]. - Zanu has captured approximately 50% of new patient prescriptions in the US for both first-line and relapsed/refractory chronic lymphocytic leukemia (CLL), positioning it as the leading BTK inhibitor globally [8]. Financial Summary - For FY24A, FY25A, and FY26E, BeOne's revenue is projected to be US$3.81 billion, US$5.34 billion, and US$6.32 billion, respectively, with net profits expected to turn positive in FY25A at US$286.9 million and further increase to US$684.5 million in FY26E [2][21]. - The company’s gross profit margin is expected to improve from 87.5% in FY25A to 87.6% in FY26E, while the net profit margin is projected to rise from 5.4% in FY25A to 10.8% in FY26E [22]. Market Performance - BeOne's market capitalization stands at approximately US$37.57 billion, with a 52-week high of US$377.47 and a low of US$206.32 [3]. - The stock has experienced a decline of 5.7% over the past month and 6.9% over the past three months, but has shown a positive trend with a 5.6% increase over the last six months [5]. Shareholding Structure - Major shareholders include Amgen with a 16.9% stake and Baker Bros with 7.9% [4].

R&D Strategy and Pipeline - BeiGene's R&D strategy focuses on developing a deep and impactful portfolio, executing fast-to-PoC for value maximization, initiating combination therapies early, and advancing only transformative medicines to late-stage development[18] - BeiGene has an extensive investment in innovative platforms, supporting a robust preclinical pipeline of 69 programs, with 51% biologics and 43% small molecules[19, 20] - BeiGene is transforming its pipeline with a focus on heme leadership and solid tumor diversification, expecting POC data readouts for many NMEs in the next 1-2 years[21] Solid Tumor Programs - BGB-43395 (CDK4i) is undergoing dose escalation in monotherapy and in combination with endocrine therapy (ET) in breast cancer patients[34] - Preliminary data from the BGB-43395-101 study shows a manageable safety profile, with diarrhea and nausea being the most commonly reported AEs[28] - BGB-43395 exhibits rapid absorption with a median Tmax of approximately 2 hours, and exposures increased approximately dose proportionately[42] Hematology Programs - Brukinsa (Zanubrutinib) - Brukinsa has demonstrated sustained PFS superiority over Ibrutinib in the ALPINE H2H study with 42.5 months follow-up, with a HR of 0.68 (95% CI: 0.54, 0.84)[74] - In the ALPINE study, Zanubrutinib showed sustained superiority and risk reduction in the TP53/Del17p population, with a HR of 0.51 (95% CI: 0.33, 0.78)[78, 80] - In the SEQUOIA study, Zanubrutinib demonstrated a sustained PFS benefit in treatment-naive unfit CLL/SLL patients, with a 71% reduction in risk of progression or death[88, 96] Hematology Programs - Sonrotoclax - In a Phase 1/1b study, Sonrotoclax combined with Zanubrutinib as frontline treatment for CLL demonstrated high MRD clearance rates, with 90% achieving uMRD by week 48 in the 320mg cohort[68, 122] - The CELESTIAL-TNCLL trial is an ongoing Phase 3 study assessing Sonrotoclax + Zanubrutinib vs Venetoclax + Obinutuzumab for treatment-naive CLL[68, 142] Hematology Programs - BTK CDAC (BGB-16673) - In a Phase 1 study, the BTK degrader BGB-16673 showed an ORR of 77.6% in heavily pre-treated R/R CLL/SLL patients, with an ORR of 93.8% at 200 mg[169, 181] - BGB-16673 demonstrated promising activity in patients with Richter Transformation, with an ORR of 58.3%[175, 180] - BGB-16673 also showed high overall response rates and VGPRs in R/R WM patients, with an ORR of 81.5%[190, 193]